分化型甲状腺癌全甲状腺切除术后撤药准备中放射性碘治疗前促甲状腺激素阈值的系统评价与荟萃分析
该系统评价与荟萃分析纳入8项回顾性队列研究共4651例经甲状腺激素撤药准备的分化型甲状腺癌成人患者,比较放射性碘治疗前不同促甲状腺激素(TSH)阈值(<30 vs ≥30、<60 vs ≥60、<90 vs ≥90 mIU/L)与肿瘤学结局的关联。结果显示,较高的治疗前TSH水平并未与更好的治疗反应、更低的复发率或更低的死亡率相关;在2年和3年随访时,卓越反应率(合并RR=0.87;CI 0.68-1.11)和不确定反应率(RR=1.28;CI 0.72-2.27)均无显著差异,复发率亦无差异(RR=1.45;CI 0.83-2.55),且无研究显示疾病特异性死亡率在不同随访期(长达10年)存在差异。证据确定性因偏倚风险、异质性和不精确性被评为极低。
要点
- 较高治疗前TSH水平未显示与更好的治疗反应、更低复发或更低死亡率相关。
- 2年和3年随访时卓越反应率与不确定反应率在TSH≥30 vs <30 mIU/L间无显著差异。
- 证据确定性极低,不足以支持或反驳常规使用特定TSH阈值。
核心结论
- 当前证据基础不足以支持或反驳放射性碘治疗前常规使用特定TSH阈值。
- 研究结果对放射性碘治疗前达到TSH≥30 mIU/L的推荐提出质疑,并强调需要试验来确定TSH刺激的最小有效水平。
研究设计与样本
- 系统评价与荟萃分析,纳入8项回顾性队列研究,共4651例经甲状腺激素撤药准备的分化型甲状腺癌成人患者。
- 检索MEDLINE、Embase、Cochrane和Scopus(自建库至2025年3月)。
- 使用CLARITY工具评估偏倚风险,使用GRADE评估证据确定性,采用随机效应模型计算合并相对风险(RR)。
- 该系统评价在PROSPERO注册(CRD42020158354)。
主要发现
- 在所有 examined 的TSH阈值(<30、<60和<90 mIU/L)中,较高的放射性碘治疗前TSH水平与更好的治疗反应、更低的复发率或降低的死亡率无关。
- 具体而言,放射性碘治疗前TSH水平较高(≥30 mIU/L)的患者与较低水平(<30 mIU/L)的患者相比,肿瘤学结局并无更好。
- 在2年和3年随访时,卓越反应率(合并RR=0.87;CI 0.68-1.11)或不确定反应率(RR=1.28;CI 0.72-2.27)无显著差异。
- 复发率无差异(RR=1.45;CI 0.83-2.55),且无研究显示在长达10年的随访期内疾病特异性死亡率存在差异。
- 所有结局的证据确定性因偏倚风险、异质性和不精确性被评为极低。
关键数值与推荐
- 比较的TSH阈值包括<30 vs ≥30、<60 vs ≥60和<90 vs ≥90 mIU/L。
- 主要结局包括疾病特异性死亡率、复发和治疗反应。
- 2年和3年随访卓越反应合并RR=0.87(CI 0.68-1.11),不确定反应RR=1.28(CI 0.72-2.27),复发RR=1.45(CI 0.83-2.55)。
- 所有结局证据确定性评为极低。
临床怎么用
- 对于经甲状腺激素撤药准备的分化型甲状腺癌患者,不应仅依据TSH≥30 mIU/L的阈值来决定是否进行放射性碘治疗。
- 临床决策应综合考虑其他因素,因当前证据不足以支持常规使用特定TSH阈值。
- 需等待随机试验确定放射性碘治疗前TSH刺激的最小有效水平。
局限性
- 纳入研究均为回顾性队列研究,存在偏倚风险。
- 研究间存在异质性和不精确性。
- 所有结局的证据确定性被评为极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preparation for radioiodine (RAI) therapy in differentiated thyroid cancer (DTC) often requires thyroid hormone withdrawal (THW) to achieve thyrotropin (TSH) stimulation. Current guidelines recommend TSH ≥30 mIU/L, a target that prolongs hypothyroidism and worsens quality of life, yet rests on limited evidence. OBJECTIVE: To evaluate the association between pre-RAI TSH levels and oncologic outcomes in adults with DTC prepared by THW. METHODS: We conducted a systematic review and meta-analysis of studies comparing outcomes across pre-RAI TSH thresholds (<30 vs. ≥30, <60 vs. ≥60, and <90 vs. ≥90 mIU/L) in adults with DTC prepared by THW. Primary outcomes included disease-specific mortality, recurrence, and response to therapy. Searches in MEDLINE, Embase, Cochrane, and Scopus (inception to March 2025) identified eligible studies. Risk of bias was assessed using the CLARITY tool and certainty of evidence using GRADE. Pooled relative risks (RRs) were calculated using random-effects models. This systematic review was registered in PROSPERO (CRD42020158354). RESULTS: This meta-analysis included eight retrospective cohort studies comprising a total of 4651 DTC patients, predominantly women (68.5%) with a mean age of 46 years. All patients underwent THW before RAI. Across all TSH thresholds examined (<30, <60, and <90 mIU/L), higher pre-RAI TSH levels were not associated with better treatment response, lower recurrence, or reduced mortality. Specifically, patients with higher pre-RAI TSH levels (≥30 mIU/L) did not have better oncologic outcomes compared with those with lower levels (<30 mIU/L). At 2- and 3-year follow-up, no significant differences were observed in excellent (pooled RR = 0.87; confidence interval [CI] 0.68-1.11) or indeterminate (RR = 1.28; CI 0.72-2.27) response rates. Similarly, recurrence rates did not differ (RR = 1.45; CI 0.83-2.55), and no study demonstrated a difference in disease-specific mortality across follow-up periods extending up to 10 years. The certainty of evidence for all outcomes was rated very low due to risk of bias, heterogeneity, and imprecision. CONCLUSIONS: The current evidence base is insufficient to support or refute the routine use of a specific TSH threshold before RAI administration. These findings question the recommendation to achieve TSH ≥30 mIU/L before RAI and highlight the need for trials to define the minimal effective level of TSH stimulation.
引用
- Rojas T, Solis-Pazmino P, Figueroa LA, et al. Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis. Thyroid. 2026. PMID: 41674098. doi:10.1177/10507256261423206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。